Luminex (Nasdaq: LMNX ) is expected to report Q4 earnings on Feb. 4. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Luminex's revenues will grow 12.9% and EPS will wane -18.2%.
The average estimate for revenue is $54.1 million. On the bottom line, the average EPS estimate is $0.09.
Last quarter, Luminex notched revenue of $50.0 million. GAAP reported sales were 9.9% higher than the prior-year quarter's $45.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.04. GAAP EPS of $0.04 for Q3 were 20% lower than the prior-year quarter's $0.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 70.0%, 320 basis points better than the prior-year quarter. Operating margin was 10.7%, 10 basis points better than the prior-year quarter. Net margin was 3.3%, 90 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $201.2 million. The average EPS estimate is $0.32.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 91 members out of 104 rating the stock outperform, and 13 members rating it underperform. Among 30 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give Luminex a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Luminex is outperform, with an average price target of $20.83.
Looking for alternatives to Luminex? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Luminex to My Watchlist.